Compounds and methods for the targeted degradation of androgen receptor
AssigneeArvinas Operations, Inc.
InventorsAndrew P. Crew, Lawrence B. Snyder, Jing Wang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.
Claims7
A compound that is:
A pharmaceutical composition comprising a compound that is:
- and a pharmaceutically acceptable carrier.
A method of treating prostate cancer in a subject in need thereof, wherein the method comprises administering to the subject a composition comprising a therapeutically effective amount of a compound that is:
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.